索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]李英英,高晓玲.阻塞性睡眠呼吸暂停与心血管疾病相关性研究进展[J].国际心血管病杂志,2022,06:356.
点击复制

阻塞性睡眠呼吸暂停与心血管疾病相关性研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年06期
页码:
356
栏目:
综述
出版日期:
2022-12-20

文章信息/Info

Title:
-
作者:
李英英; 高晓玲
030001 太原，山西医科大学第二医院呼吸与危重症医 学科
Author(s):
-
关键词:
阻塞性睡眠呼吸暂停; 高血压; 心律失常; 动脉粥样硬化
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.06.011
文献标识码:
-
摘要:
阻塞性睡眠呼吸暂停（OSA）与高血压、心律失常、动脉粥样硬化密切相关。 微小RNA（miRNA）-126a-3p 可能是治疗OSA 相关高血压的潜在治疗靶点，Toll 样受 体4/ 核因子κB 是治疗动脉粥样硬化的潜在靶点，RNA 在OSA 相关心血管疾病检测和治 疗方面显示出其潜力。
Abstract:
-

参考文献/References

[1] St?whas AC, Lichtblau M, Bloch KE. Obstructive sleep apnea syndrome[J]. Praxis (Bern 1994), 2019, 108(2):111-117.
[2] Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis[J]. Lancet Respir Med, 2019, 7(8): 687-698.
[3] Veasey SC, Rosen IM. Obstructive sleep apnea in adults[J]. N Engl J Med, 2019, 380(15):1442-1449.
[4] Salari N, Khazaie H, Abolfathi M, et al. The effect of obstructive sleep apnea on the increased risk of cardiovascular disease: a systematic review and meta-analysis[J]. Neurol Sci, 2022, 43(1):219-231.
[5] Maniaci A, Iannella G, Cocuzza S, et al. Oxidative stress and inflammation biomarker expression in obstructive sleep apnea patients[J]. J Clin Med, 2021, 10(2):277.
[6] Wang F, Liu Y, Xu H, et al. Association between upper-airway surgery and ameliorative risk markers of endothelial function in obstructive sleep apnea[J]. Sci Rep, 2019, 9(1):20157.
[7] Lino DOC, Freitas IA, Meneses GC, et al. Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure[J]. Braz J Med Biol Res, 2019, 52(12):e8658.
[8] Oyarce MP, Iturriaga R. Contribution of oxidative stress and inflammation to the neurogenic hypertension induced by intermittent hypoxia[J]. Front Physiol, 2018, 9:893.
[9] Prabhakar NR, Peng YJ, Nanduri J. Hypoxia-inducible factors and obstructive sleep apnea[J]. J Clin Invest, 2020, 130(10): 5042-5051.
[10] Arnaud C, Bochaton T, Pépin JL, et al. Obstructive sleep apnoea and cardiovascular consequences: pathophysiological mechanisms[J]. Arch Cardiovasc Dis, 2020, 113(5):350- 358.
[11] He L, Liao X, Zhu G, et al. MiR-126a-3p targets HIF-1α and alleviates obstructive sleep apnea syndrome with hypertension[J]. Hum Cell, 2020, 33(4):1036-1045.
[12] Oscullo G, Sapi?a-Beltrán E, Torres G, et al. The potential role of obstructive sleep apnoea in refractory hypertension[J]. Curr Hypertens Rep, 2019, 21(8):57.
[13] Di Fusco SA, Pignalberi C, Santini L, et al. Arrhythmias and sleep apnea: physiopathologic Link and clinical implications[J]. J Interv Card Electrophysiol, 2020, 57(3): 387-397.
[14] Wang X, Yue Z, Liu Z, et al. Continuous positive airway pressure effectively ameliorates arrhythmias in patients with obstructive sleep apnea-hypopnea via counteracting the inflammation[J]. Am J Otolaryngol, 2020, 41(6):102655.
[15] Imamura T, Xue J, Poulsen O, et al. Intermittent hypoxia and hypercapnia induces inhibitor of nuclear factor-κB kinase subunit β-dependent atherosclerosis in pulmonary arteries[J]. Am J Physiol Regul Integr Comp Physiol, 2019, 317(6):R763-R769.
[16] Song D, Fang G, Mao SZ, et al. Selective inhibition of endothelial NF-κB signaling attenuates chronic intermittent hypoxia-induced atherosclerosis in mice[J]. Atherosclerosis, 2018, 270:68-75.
[17] Zeng X, Guo R, Dong M, et al. Contribution of TLR4 signaling in intermittent hypoxia-mediated atherosclerosis progression[J]. J Transl Med, 2018, 16(1):106.
[18] Olejarz W, G?uszko A, Cyran A, et al. TLRs and RAGE are elevated in carotid plaques from patients with moderate-tosevere obstructive sleep apnea syndrome[J]. Sleep Breath, 2020, 24(4):1573-1580.
[19] Eisele HJ, Markart P, Schulz R. Obstructive sleep apnea, oxidative stress, and cardiovascular disease: evidence from human studies[J]. Oxid Med Cell Longev, 2015, 2015:608438.
[20] Arnaud C, Bouyon S, Recoquillon S, et al. Nonmuscle myosin light chain kinase: a key player in intermittent hypoxiainduced vascular alterations[J]. J Am Heart Assoc, 2018, 7(3): e007893.
[21] Avezov K, Aizenbud D, Lavie L. Intermittent hypoxia induced formation of "Endothelial Cell-Colony Forming Units (ECCFUs)" is affected by ROS and oxidative stress[J]. Front Neurol, 2018, 9:447.
[22] Belaidi E, Morand J, Gras E, et al. Targeting the ROSHIF- 1-endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications[J]. Pharmacol Ther, 2016, 168:1-11.
[23] Prabhakar NR, Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2[J]. Physiol Rev, 2012, 92(3):967-1003.
[24] Gabryelska A, ?ukasik ZM, Makowska JS, et al. Obstructive sleep apnea: from intermittent hypoxia to cardiovascular complications via blood platelets[J]. Front Neurol, 2018, 9:635.
[25] Chen J, Lin S, Zeng Y. An update on obstructive sleep apnea for atherosclerosis: mechanism, diagnosis, and treatment[J]. Front Cardiovasc Med, 2021, 8:647071.
[26] Khalyfa A, Zhang C, Khalyfa AA, et al. Effect on intermittent hypoxia on plasma exosomal micro RNA signature and endothelial function in healthy adults[J]. Sleep, 2016, 39(12): 2077-2090.
[27] Zhang J, Hu C, Jiao X, et al. Potential role of mRNAs and lncRNAs in chronic intermittent hypoxia exposure-aggravated atherosclerosis[J]. Front Genet, 2020, 11:290.
[28] Chen Q, Lin G, Huang J, et al. Inhibition of miR-193a-3p protects human umbilical vein endothelial cells against intermittent hypoxia-induced endothelial injury by targeting FAIM2[J]. Aging (Albany NY), 2020, 12(2):1899-1909.
[29] Lin G, Huang J, Chen Q, et al. MiR-146a-5p mediates intermittent hypoxia-induced injury in H9c2 cells by targeting XIAP[J]. Oxid Med Cell Longev, 2019, 2019:6581217.
[30] Sofer T, Li R, Joehanes R, et al. Low oxygen saturation during sleep reduces CD1D and RAB20 expressions that are reversed by CPAP therapy[J]. EBioMedicine, 2020, 56:102803.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81870076）
通信作者：高晓玲， E-mail：yihexiyuan@qq.com
更新日期/Last Update: 2022-12-20